Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Salicylamide Sodium
2. Salicylamide Sulfate
3. Salicylamide, 3h-labeled
4. Salicylamide, Calcium (2:1) Salt
5. Salicylamide, Monosodium Salt
1. 2-hydroxybenzamide
2. 65-45-2
3. O-hydroxybenzamide
4. Benzamide, 2-hydroxy-
5. Salicylic Acid Amide
6. 2-carbamoylphenol
7. Salamide
8. Urtosal
9. 2-carboxamidophenol
10. Flarpirina
11. Morsarinas
12. Algamon
13. Algiamida
14. Allevin
15. Amidosal
16. Andasol
17. Cetamide
18. Dolomide
19. Dropsprin
20. Eggosalil
21. Liquiprin
22. Novecyl
23. Panithal
24. Raspberin
25. Saliamid
26. Saliamin
27. Salicim
28. Salipur
29. Salizell
30. Salymid
31. Serramida
32. Acket
33. Anamid
34. Oramid
35. Salrin
36. Afko-sal
37. Amid-sal
38. Benzamide, O-hydroxy-
39. Salicilamida
40. Salicilamide
41. Salicylamidum
42. Amid Kyseliny Salicylove
43. Ohb
44. Nsc 3115
45. Mfcd00007978
46. 2-hydroxy-benzamide
47. H.p. 34
48. Sr 4326
49. Nsc-3115
50. Em8bm710zc
51. Chembl27577
52. Mls000069486
53. Chebi:32114
54. Ncgc00091414-02
55. Smr000046394
56. Salicylamide 100 Microg/ml In Acetonitrile
57. Dsstox_cid_1726
58. Dsstox_rid_76295
59. Dsstox_gsid_21726
60. Salizell (van)
61. Benesal (van)
62. Salicilamide [dcit]
63. Salicilamide [italian]
64. Salicylamidum [inn-latin]
65. Cas-65-45-2
66. Salicilamida [inn-spanish]
67. Ccris 6045
68. Hsdb 227
69. Amid Kyseliny Salicylove [czech]
70. Benzoic Acid, 2-hydroxy-, Amide
71. Einecs 200-609-3
72. Unii-em8bm710zc
73. Brn 0742439
74. Salicylamid
75. Samid
76. Ai3-03454
77. Hydroxy Benzamide
78. Saliclamide,(s)
79. Dihydroxybenzalamine
80. 2-oxidanylbenzamide
81. Salicylamide [usp:inn:ban:jan]
82. Salicylamide (tn)
83. Salicylamide, 99%
84. Spectrum_000946
85. Opera_id_1684
86. Spectrum2_001312
87. Spectrum3_000564
88. Spectrum4_000499
89. Spectrum5_001032
90. Salicylamide [mi]
91. Wln: Zvr Bq
92. Salicylamide [inn]
93. Salicylamide [jan]
94. Ec 200-609-3
95. Salicylamide [hsdb]
96. Salicylamide [inci]
97. Nciopen2_001127
98. Salicylamide [vandf]
99. Oprea1_069894
100. Schembl21646
101. Bspbio_001948
102. Kbiogr_001017
103. Kbioss_001426
104. Salicylamide [mart.]
105. 4-10-00-00169 (beilstein Handbook Reference)
106. Divk1c_000858
107. Salicylamide [usp-rs]
108. Salicylamide [who-dd]
109. Spectrum1500532
110. Salicylamide (jan/usp/inn)
111. Spbio_001403
112. Zinc2055
113. Dtxsid3021726
114. Hms502k20
115. Kbio1_000858
116. Kbio2_001426
117. Kbio2_003994
118. Kbio2_006562
119. Kbio3_001448
120. Nsc3115
121. Ninds_000858
122. Hms1920p14
123. Hms2092g15
124. Hms2232e07
125. Pharmakon1600-01500532
126. Component Of Tolagesic (salt/mix)
127. Hy-b0811
128. Salicylamide [usp Monograph]
129. Tox21_111129
130. Tox21_201944
131. Tox21_302801
132. Bbl016007
133. Bdbm50056900
134. Ccg-39250
135. Nsc757318
136. S6404
137. Stk301812
138. Akos000120983
139. Tox21_111129_1
140. Cs-7630
141. Db08797
142. Nsc-757318
143. Idi1_000858
144. Ncgc00091414-01
145. Ncgc00091414-03
146. Ncgc00091414-04
147. Ncgc00091414-05
148. Ncgc00091414-07
149. Ncgc00256376-01
150. Ncgc00259493-01
151. Ds-16216
152. Salicylamide, Puriss., >=99.0% (t)
153. Sbi-0051509.p003
154. Eu-0000058
155. Ft-0659360
156. S0006
157. D01811
158. Ab00052089_12
159. A835120
160. Ah-034/32461056
161. Sr-01000721923
162. Benzoic Acid,2-hydroxy,amide Salicylamide
163. J-509663
164. Q2496906
165. Sr-01000721923-2
166. Brd-k81130846-001-02-6
167. Brd-k81130846-001-12-5
168. Z68590124
169. Salicylamide, United States Pharmacopeia (usp) Reference Standard
170. Salicylamide, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 137.14 g/mol |
|---|---|
| Molecular Formula | C7H7NO2 |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 137.047678466 g/mol |
| Monoisotopic Mass | 137.047678466 g/mol |
| Topological Polar Surface Area | 63.3 Ų |
| Heavy Atom Count | 10 |
| Formal Charge | 0 |
| Complexity | 136 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Salicylamide, which is not metabolized to salicylate in vivo, has antipyretic, analgesic, and antiinflammatory effects similar to those of salicylate.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 650
SALICYLAMIDE, THE AMIDE OF SALICYLIC ACID, IS NO LONGER AN OFFICIAL DRUG. ITS EFFECTS IN MAN ARE NOT RELIABLE, & ITS USE IS NOT RECOMMENDED. THE SMALL DOSES INCLUDED IN "OVER-THE-COUNTER" ANALGESIC AND SEDATIVE MIXTURES ARE PROBABLY INEFFECTIVE.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 695
THIRD MOST COMMON COMPONENT OF NONPRESCRIPTION HYPNOTIC MIXT IS SODIUM SALICYLAMIDE. DOSE OF 1.3 G HAS SLIGHT SEDATIVE EFFECT; DOSE INCL IN NONPRESCRIPTION PRODUCTS IS 200-380 MG. /SODIUM SALICYLAMIDE/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 369
MEDICATION (VET): DEPRESSES INTESTINAL SMOOTH MUSCLE FUNCTION IN RABBIT & DOG TRIALS. MOST PROMISING INDICATION IN VET MEDICINE MAY BE FOR DOGS WITH CALCIUM PHOSPHATE CONTAINING URINARY CALCULI WHICH ITS COMPLEX GLUCURONIDE METABOLITES MAY HELP SOLUBILIZE.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 518
For more Therapeutic Uses (Complete) data for SALICYLAMIDE (10 total), please visit the HSDB record page.
RESULTS OF THE FEW ACCEPTABLE CONTROLLED STUDIES ON SALICYLAMIDE INDICATE THAT THIS AGENT IS MUCH LESS EFFECTIVE THAN ASPIRIN AS ANALGESIC OR ANTIPYRETIC WHEN GIVEN IN SAME DOSE & THEREFORE IS TOO WEAK & UNRELIABLE TO BE USEFUL.
American Medical Association, Council on Drugs. AMA Drug Evaluations. 2nd ed. Acton, Mass.: Publishing Sciences Group, Inc., 1973., p. 265
VET: WARNING: CATS MAY BE VERY SENSITIVE TO TOXIC EFFECT OF THIS DRUG.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 518
Dose related GI and CNS disturbances are the most common adverse effects of salicylamide. GI disturbances may include nausea, vomiting, heartburn, anorexia, or diarrhea. CNS disturbances may include dizziness, drowsiness, lightheadedness, faintness, or headache. Flushing, hyperventilation, sweating, dry mouth, rash, and thrombocytopenic purpura have also been reported. Adverse Gi and CNS effects occur infrequently with salicylamide doses occur infrequently with salicylamide doses of 325-650 mg but occur often with higher doses. Tinnitus, ecchymoses, hemorrhagic lesions, leukopenia, or thrombocytopenia may also occur with high doses.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 95. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1995 (Plus Supplements 1995)., p. 1417
3. 3= MODERATELY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) 0.5-5 G/KG, BETWEEN 1 OUNCE AND 1 PINT (OR 1 LB) FOR 70 KG PERSON (150 LB).
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-138
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
N - Nervous system
N02 - Analgesics
N02B - Other analgesics and antipyretics
N02BA - Salicylic acid and derivatives
N02BA05 - Salicylamide
WHEN...GIVEN ORALLY...IT IS ABSORBED AND EXCRETED SO RAPIDLY THAT HIGH PLASMA LEVELS ARE NOT OBTAINED. IT DIFFUSES QUICKLY INTO THE VARIOUS BODY TISSUES AND INTO A MUCH GREATER APPARENT VOLUME OF BODY WATER... ANIMAL STUDIES SHOW...DIFFUSION RAPIDLY INTO THE BRAIN.
Di Palma, J. (ed.). Drill's Pharmacology in Medicine. 4th ed. New York: McGraw Hill Book Co., 1971., p. 401
/IN THE RABBIT/ RATE OF TRANSPORT OF FREE DRUG ACROSS BASAL BARRIER WAS BLOOD-FLOW-LIMITED, WHILE TRANSPORT OF THE GLUCURONIDE WAS LIMITED BY TRANSPORT STEP OUT OF EPITHELIAL CELL RATHER THAN BY RATE OF SYNTHESIS.
The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 424
...WHEN DOSE OF SALICYLAMIDE EXCEEDS ABOUT 1 G...SIGNIFICANT LEVELS OF UNCHANGED DRUG APPEAR IN PLASMA.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 28:08
BIOAVAILABILITY STUDIES IN HUMAN/S/...INDICATED THAT SODIUM SALICYLAMIDE IN SOLN IS ABSORBED FASTER AFTER ORAL DOSES THAN SALICYLAMIDE IN TABLETS. SEDATIVE EFFECT OCCURRED EARLIER WITH NA SALT THAN WITH SALICYLAMIDE & EXTENT OF SEDATION INCR WITH INCR DOSES OF BOTH COMPD.
The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 5: A Review of the Literature Published during 1976 and 1977. London: The Chemical Society, 1979., p. 25
For more Absorption, Distribution and Excretion (Complete) data for SALICYLAMIDE (9 total), please visit the HSDB record page.
SALICYLAMIDE IS CONJUGATED BY INTESTINAL MUCOSA AFTER ORAL ADMINISTRATION...
American Medical Association, Council on Drugs. AMA Drug Evaluations. 2nd ed. Acton, Mass.: Publishing Sciences Group, Inc., 1973., p. 265
AFTER ADMIN OF SALICYLAMIDE TO CATS NO GLUCURONIDE CONJUGATE COULD BE DETECTED IN URINE. INCR AMT OF SULFURIC ACID ESTER CONJUGATE & SUBSTANTIALLY GREATER AMT OF 2,3-DIHYDROXYBENZAMIDE WERE PRODUCED BY CAT COMPARED WITH RABBIT.
The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 4: A Review of the Literature Published during 1974 and 1975. London: The Chemical Society, 1977., p. 367
SALICYLAMIDE GIVES SALICYLAMIDE-2-BETA-D-GLUCURONIDE & SALICYLAMIDE-2-SULFATE IN MAN. /FROM TABLE/
Goodwin, B.L. Handbook of Intermediary Metabolism of Aromatic Compounds. New York: Wiley, 1976., p. S-3
AFTER ADMIN OF 5 MG/KG SALICYLAMIDE IN 5 MG/KG TYLENOL SUSPENSION, CHILDREN EXCRETED 78% OF DOSE AS SALICYLAMIDE SULFATE; ADULTS 36%. IN ADULTS, GLUCURONIDE WAS MAJOR PRODUCT. GLUCURONIDE CONJUGATION DEFICIENCY IN CHILDREN IS ACCOMPANIED BY A HIGHER RATE OF SULFATE FORMATION.
PMID:830879 ROBERTS ET AL; J PEDIATR 90 (JAN): 130 (1977)
For more Metabolism/Metabolites (Complete) data for SALICYLAMIDE (10 total), please visit the HSDB record page.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Disintegrants & Superdisintegrants
Lubricants & Glidants
Granulation
Thickeners and Stabilizers
Co-Processed Excipients
Controlled & Modified Release
Coating Systems & Additives
Solubilizers
Film Formers & Plasticizers
Taste Masking
Chewable & Orodispersible Aids
Emulsifying Agents
Rheology Modifiers
Parenteral
API Stability Enhancers
Topical
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
